In newly diagnosed AML patients, splicesome mutations including SRSF2, F3B1, U2AF1, or ZRSR2 are now considered pathognomonic of secondary AML developing from precedent MDS [57]. Here, SRSF2 is linked to acute myeloid leukemia.